Graph not available
Graph not available

Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

Hester Biosciences Ltd Performance

Today's Low
1,741.70
arrowIcon
Today's High
1,810.00
52 Wk Low
1,292.85
arrowIcon
52 Wk High
1,939.95


Open

1754.3

Traded Value (Cr)

0.86

Prev. Close

1779.15

Face Value

10

Volume

4838

Hester Biosciences Ltd Fundamentals

Market Cap
₹ 1510.31 Cr
P/E Ratio (TTM)
79.97
P/B Ratio
5.18
Debt to Equity
0.93
ROE
11.53
EPS (TTM)
22.20
Dividend Yield
0.34 %
Book Value
343.01

Click here to know more about Fundamentals

Hester Biosciences Ltd Financials

Hester Biosciences Ltd Financials

Hester Biosciences Ltd Shareholding Pattern

Held By Mar 2024 Dec 2023 Sep 2023 Jun 2023
Promoters 53.73 % 53.73 % 53.73 % 53.73 %
Retail 33.32 % 33.30 % 33.19 % 33.36 %
Others 12.52 % 12.54 % 12.66 % 12.46 %
FII 0.43 % 0.43 % 0.42 % 0.45 %
Mutual Funds 0.00 % 0.00 % 0.00 % 0.00 %

Promoters

53.73%

Retail

33.32%

Others

12.52%

FII

0.43%

Mutual Funds

0.00%

Promoters

53.73%

Retail

33.30%

Others

12.54%

FII

0.43%

Mutual Funds

0.00%

Promoters

53.73%

Retail

33.19%

Others

12.66%

FII

0.42%

Mutual Funds

0.00%

Promoters

53.73%

Retail

33.36%

Others

12.46%

FII

0.45%

Mutual Funds

0.00%

Resistance and Support

₹1,776.95

PIVOT

resistance-arrow
Resistance
First Resistance₹1,812.200
Second Resistance₹1,845.250
Third Resistance₹1,880.500
support-arrow
Support
First Support₹1,743.900
Second Support₹1,708.650
Third Support₹1,675.600

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day6,8321,17458.26
Week4,8382,381-75.15
1 Month4,8384,409-75.15
6 Months1,122,814704,50867.14

About Hester Biosciences Ltd

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India. Since its incorporation in Apr' 87, the Company has been engaged in the production and distribution of vaccines and health products. Headquartered in Ahmedabad, Gujarat, the Company is currently the second-largest maker of poultry vaccines in India, having acquired strong brand equity over the years. The Company principally engages in two business verticals, namely Poultry Healthcare and Animal Healthcare. Its products are registered with several countries, and internal agencies, and have gained widespread recognition in both India and international markets. It has built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh. The products and services offered include over 51 vaccines and 70+ health products. In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals. The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents. It markets the veterinary products of many international companies including Ghen Corporation, Japan; Maine Biological Laboratories, US; Idexx Corporation, US; International Diagnostic Systems Corporation, US; Biogal Galed Laboratories, Israel; and Kemin Europa, Belgium. The company's own production of veterinary vaccines (in Vials) is expected to commence soon. HPL has technical collaborations with Maine Biological Laboratories and Ghen Corporation. During 1996-97, company successfully implemented veterinary vaccine and commercial production has begun. The company received licenses for producing 10 additional poultry vaccines. It signed a manufacturing agreement with Sinsui Inc for producing poultry vaccines. In 2003, Hester was appointed as the exclusive Indian distributor by BIOPHARM of Czech Republic, for their coccidiosis vaccine - LIVACOX. Hester commenced business with Merial in the 3rd quarter of the financial year by importing poultry vaccines from them in 2004-05 and therefore, name of Company was changed from HESTER PHARMACEUTICALS LIMITED to HESTER BIOSCIENCES LIMITED. The Company embarked on an expansion program, to increase its capacity from 1200 million doses to 4800 million doses, which was commenced in January 2006. The expansion project and the new expanded capacity went on-stream in March 2007. The distribution network within India was made functional with company managed depots at Pune, Bangalore, Coimbatore, Hyderabad and Chandigarh, having state-of-art cold store facilities to maintain the cold chain. Distribution costs were further cut by embarking on the use of company owned refrigerated vans for deliveries all across India. In January 2010, the company re-launched the freeze dried MD Vaccine after 5 years. A JV was set-up in Nepal to facilitate manufacture of specific animal vaccines for international markets in 2011 for a project which costed Rs 15 crores. New technology was acquired. The Company signed a technology transfer agreement with Indian Veterinary Research Institute for acquiring technology to manufacture PPR and Sheep Pox vaccines in 2011. Company re-launched the bivalent Marek's Disease Live vaccine for the poultry, containing HVT & SB1 strains in 2012-13. It operationalised large animal vaccines division in Mar' 15. During the financial year 2014-15, Gujarat Agrofarm Limited became a wholly owned subsidiary of the Company. During financial year 2015-16, three wholly owned subsidiary Companies namely Gujarat Agrofarm Limited, Diavetra Lifesciences Private Limited and Hester Biosciences (Mauritius) Limited got merged with Company through a Scheme of Arrangement effective on 8 December 2015. Accordingly, the Company allotted and listed its 65 Equity Shares pursuant to Scheme of Arrangement vide order passed by Hon'ble High Court of Gujarat dated 8 December 2015 and the said Shares were listed at NSE Limited and BSE Limited in March, 2016. Leruarua Vetcare (Proprietary) Limited, incorporated in Botswana became an Associate Company with 49% stake of the Company and Innoves Animal Health Private Limited ceases to be an Associate Company due to transfer of shareholding of the Company in FY 2015-16. The Nepal unit completed trial operations and began commercial manufacturing in November, 2016. Leruarua Vetcare (Proprietary) Limited, Botswana ceases to be an Associate Company due to buyback of entire shareholding by the Associate Company during the FY 2016-17. The Company held 65% stake in subsidiary Company, Hester Biosciences Nepal Private Limited (HBNPL) and consequently, HBNPL became a subsidiary of Hester Biosciences Limited (Parent Company) during FY 2016-17. During the year 2017-18, Company acquired 54.80% in the capital of Texas Laboratories, a firm having a business place at Mehsana Distt. of Gujarat. In June 2017, Texas Laboratories converted into Private Limited Company namely, Texas Lifesciences Private Limited. Further, the Company incorporated 100% wholly-owned subsidiary, Hester Biosciences Africa Limited in Tanzania. During the year 2018-19, Hester Biosciences Limited incorporated 100% wholly-owned subsidiary Hester Biosciences Kenya Limited in Kenya.

Managing Director

1987

Founded

Rajiv D Gandhi

NSE Symbol

HESTERBIO

Hester Biosciences Ltd Management

NameDesignation
Bhupendra V GandhiChairman & Non Executive Dir.
Sanjiv D GandhiNon-Exec & Non-Independent Dir
Nina GandhiNon Executive Director
Sandhya PatelIndependent Non Exe. Director
Ashok BhadakalIndependent Non Exe. Director
Ameet DesaiIndependent Non Exe. Director
Rajiv D GandhiED / MD / CEO / Promoter
Ravin GandhiNon-Exec & Non-Independent Dir
PRIYA RAJIV GANDHIExecutive Director
Anil JainIndependent Non Exe. Director
Jatin Yagneshbhai TrivediIndependent Non Exe. Director

Hester Biosciences Ltd News

Board of Hester Biosciences recommends final dividend
Of Rs 6 per share
Hester Biosciences consolidated net profit rises 9.27% in the March 2024 quarter
Sales rise 17.77% to Rs 79.26 crore
Hester Biosciences to hold board meeting
On 10 May 2024
Hester Biosciences consolidated net profit declines 64.43% in the December 2023 quarter
Sales decline 10.62% to Rs 66.98 crore
Hester Biosciences to declare Quarterly Result
On 2 February 2024
Hester Biosciences consolidated net profit declines 41.07% in the September 2023 quarter
Sales decline 3.68% to Rs 70.46 crore
Hester Biosciences to conduct board meeting
On 7 November 2023
Hester Biosciences to conduct AGM
On 20 September 2023
Hester Biosciences fixes record date for final dividend
Record date is 13 September 2023
Hester Biosciences rises after Q1 PAT jumps 29% YoY to Rs 11 cr
Hester Biosciences advanced 2.58% to Rs 1,773.60 after the company's standalone net profit rose 29.4% to Rs 10.73 crore on 59.03% jump in net sales to Rs 80.34 crore in Q1 FY24 over Q1 FY23.

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
Sun Pharmaceuticals Industries Ltd₹ 358724.57 Cr
₹ 1,495.10
(-2.87 %)
87.07
Cipla Ltd₹ 120233.22 Cr
₹ 1,489.15
(0.46 %)
32.36
Zydus Lifesciences Ltd₹ 109282.04 Cr
₹ 1,086.05
(0.50 %)
31.67
Divis Laboratories Ltd₹ 109187.23 Cr
₹ 4,113.00
(1.34 %)
80.00
Dr Reddys Laboratories Ltd₹ 98384.41 Cr
₹ 5,897.70
(0.42 %)
22.64

Hester Biosciences Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase Hester Biosciences Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. Hester Biosciences Ltd's share price is ₹1,779.15 as of May 23, 2024 at 04:14 PM

Hester Biosciences Ltd's P/E ratio is 79.97 times as of May 23, 2024 at 04:14 PM.

Hester Biosciences Ltd's most recent financial reports indicate a price-to-book ratio of 5.18, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. Hester Biosciences Ltd's market is 1,510 Cr as on May 23, 2024 at 04:14 PM.

The current financial records of Hester Biosciences Ltd show a 11.53% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

According to Hester Biosciences Ltd's most recent financial filings, the company has a total asset value of Crores, which includes current and non-current assets such as inventory, cash, properties, and equipment.

The 52-week high/low price of a Hester Biosciences Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. Hester Biosciences Ltd's 52-week high and low as of May 23, 2024 at 04:14 PM are ₹1939.95 and ₹1939.95 respectively.

As of the Mar 2024 quarter, the promoter shareholding in Hester Biosciences Ltd stands at 53.73%. During the same period, Institutional Investors have shown a slight values are equal in their holdings, values are equal from 0.43% to 0.43%.